Great Point Partners LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Great Point Partners LLC disclosed 26 US equity positions worth $212.2m in its Q4 2024 13F filing. The largest position was IONS at 8.3% of the reported book, followed by CYTK and 4XC1. Against the Q3 2024 filing, it opened 5 new positions, added to 5 and reduced 12 among the top 26 holdings.
What did Great Point Partners LLC own in Q4 2024? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 8.3% | $17.7m | 505,007 | 98% | added |
| 2 | CYTK CYTOKINETICS INC | Healthcare | 8.0% | $16.9m | 360,000 | 14% | added |
| 3 | 4XC1 KALVISTA PHARMACEUTICALS INC | 7.1% | $15.1m | 1,787,003 | 38% | added | |
| 4 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 6.8% | $14.4m | 750,000 | 0% | held |
| 5 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 6.5% | $13.9m | 1,055,000 | -45% | reduced |
| 6 | ABVX ABIVAX SA | 5.7% | $12.1m | 1,648,523 | -23% | reduced | |
| 7 | DVAX DYNAVAX TECHNOLOGIES CORP | 5.2% | $11.0m | 860,000 | -35% | reduced | |
| 8 | NGNE NEUROGENE INC | 4.8% | $10.1m | 442,761 | -56% | reduced | |
| 9 | EOLS EVOLUS INC | Healthcare | 4.7% | $9.9m | 895,524 | -23% | reduced |
| 10 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.5% | $9.6m | 245,272 | – | new |
| 11 | UNCY UNICYCIVE THERAPEUTICS INC | 4.1% | $8.7m | 10,980,000 | 28% | added | |
| 12 | ZURA ZURA BIO LTD | Healthcare | 3.7% | $7.9m | 3,170,194 | -3% | reduced |
| 13 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 3.3% | $7.1m | 3,009,392 | 7% | added |
| 14 | JSPR JASPER THERAPEUTICS INC | 3.2% | $6.9m | 322,380 | 0% | held | |
| 15 | MERUS N V | 3.1% | $6.6m | 158,092 | -37% | reduced | |
| 16 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.8% | $6.0m | 275,000 | 0% | held |
| 17 | HELIX ACQUISITION CORP II | 2.5% | $5.2m | 500,000 | 0% | held | |
| 18 | UPB UPSTREAM BIO INC | 2.3% | $4.9m | 300,000 | – | new | |
| 19 | CNTX CONTEXT THERAPEUTICS INC | 2.3% | $4.9m | 4,683,711 | -32% | reduced | |
| 20 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.2% | $4.7m | 826,751 | -14% | reduced |
| 21 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.1% | $4.4m | 228,803 | -56% | reduced |
| 22 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 1.9% | $4.0m | 1,150,000 | – | new |
| 23 | RZLT REZOLUTE INC | 1.4% | $3.0m | 621,894 | – | new | |
| 24 | PROMIS NEUROSCIENCES INC | 1.2% | $2.5m | 2,645,128 | -5% | reduced | |
| 25 | OPTNUSD OPTINOSE INC | 1.2% | $2.5m | 370,269 | – | new | |
| 26 | URGN UROGEN PHARMA LTD | Healthcare | 0.9% | $2.0m | 187,843 | -75% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.